Oncolytics Biotech (ONCY) Stock Rating Reiterated at Buy

H.C. Wainwright has reiterated its buy rating for Oncolytics Biotech (ONCY). The firm stated that they continue to see potential in the company's product pipeline. This rating is expected to influence investor sentiment positively. Oncolytics Biotech is actively involved in the development of therapies for cancer, which could impact future market performance based on clinical results.